⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7041412 | 0.71 | — | — | |
| SCHEMBL14934177 | 0.71 | — | — | |
| SCHEMBL7042252 | 0.71 | — | — | |
| SCHEMBL28205585 | 0.71 | — | — | |
| SCHEMBL28232182 | 0.67 | — | — | |
| SCHEMBL28276166 | 0.66 | — | — | |
| SCHEMBL28189174 | 0.66 | — | — | |
| SCHEMBL28146512 | 0.66 | — | — | |
| SCHEMBL27462395 | 0.64 | — | — | |
| SCHEMBL20042488 | 0.48 | DAO (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067898-B1 | Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-30 | — | — | US | disclosed |
| US-20140275179-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| WO-2005056536-A1 | ANTIDIABETIC AGENTS WHICH EXHIBIT ACTIVITY AGAINST PPAR | RANBAXY LABORATORIES LIMITED (IN) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005021520-A1 | SUBSTITUTED 1,2,4-THIADIAZOLES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2005-03-10 | — | — | WO | disclosed |